GUFICBIO
Gufic Biosciences
Each stock's 10,000-path forecast, rendered as light.
Gufic Biosciences (GUFICBIO) Stock Analysis & Case Study
Is GUFICBIO a good buy? The data-driven verdict.
Gufic Biosciences (GUFICBIO) trades at ₹360,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 27/100.
On the numbers, Gufic Biosciences (GUFICBIO) high-risk on the numbers, a Downstox Snapshot Score of 27/100, weighing expensive at 56.2× earnings, ROE of 10.1%, a 42% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
GUFICBIO fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is GUFICBIO overvalued? GUFICBIO P/E vs its sector
GUFICBIO's P/E of 56.2× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.03% dividend yield is below the peer median of 1.65%.
GUFICBIO share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of GUFICBIO history (-0%/yr drift, 37%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| GUFICBIO 2027 | ₹204 | ₹328 | ₹529 | -8% |
| GUFICBIO 2028 | ₹155 | ₹303 | ₹603 | -15% |
| GUFICBIO 2029 | ₹123 | ₹283 | ₹647 | -20% |
| GUFICBIO 2030 | ₹99 | ₹261 | ₹677 | -27% |
| GUFICBIO 2031 | ₹83 | ₹244 | ₹709 | -31% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability GUFICBIO goes up, or doubles?
The bull case for GUFICBIO
- Gufic Biosciences is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹647.
The bear case & risks
- A rich 56.2× P/E leaves a thin margin of safety if growth slows.
- Return on equity is a soft 10.1%, capital efficiency trails higher-quality peers.
- The probability model is cautious 12 months out, only a 42% chance of finishing above today's price.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹123.
GUFICBIO volatility & expected range, how bumpy is the ride?
Over the last 2.0 years GUFICBIO compounded at -0%/year with annualized volatility of 37%. That volatility implies a 1-year 80% range of ₹204–₹529, the honest backbone behind any single price target.
GUFICBIO price forecast, the full 60-month probability fan
GUFICBIO price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds GUFICBIO hits common targets within the simulated horizon?
Full multi-horizon detail on the GUFICBIO price target & forecast page.
GUFICBIO Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. GUFICBIO scores 4/9,mixed financial health.
GUFICBIO MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy GUFICBIO with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 35.0% | 2.9× |
| Zerodha | 50.0% | 2.0× |
| Dhan | 40.0% | 2.5× |
Compare every broker on the GUFICBIO MTF page.
GUFICBIO vs peers,sector comparison
About Gufic Biosciences: sector, index & market-cap context
Gufic Biosciences (GUFICBIO) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index group, with a market capitalisation of ₹3,607 Cr. See more Nifty 500 stocks.
How the GUFICBIO Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Gufic Biosciences's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
GUFICBIO analysis, FAQs
Is Gufic Biosciences (GUFICBIO) a good buy?
On the numbers, Gufic Biosciences (GUFICBIO) high-risk on the numbers, a Downstox Snapshot Score of 27/100, weighing expensive at 56.2× earnings, ROE of 10.1%, a 42% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is GUFICBIO overvalued or undervalued?
GUFICBIO trades at 56.2× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the GUFICBIO share price target for 2031?
GUFICBIO's probability-weighted 2031 median target is ₹244, with an 80% range of ₹83–₹709 (10,000-path Monte-Carlo).
What is the probability GUFICBIO doubles in 5 years?
The modelled probability of GUFICBIO reaching ₹711 (2×) within 5 years is 10%.
What is the bull case for GUFICBIO?
Gufic Biosciences is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in GUFICBIO?
A rich 56.2× P/E leaves a thin margin of safety if growth slows. Return on equity is a soft 10.1%, capital efficiency trails higher-quality peers. The probability model is cautious 12 months out, only a 42% chance of finishing above today's price.